Oncogenic mutations in the BRAF gene are detected in ∼ 7% of human cancer samples with a particularly high frequency of mutation in malignant melanomas. Over 40 different missense BRAF mutations have been found, but the vast majority (>90%) represent a single nucleotide change resulting in a valine → glutamate mutation at residue 600 ( V600E BRAF). In cells cultured in vitro, V600E BRAF is able to stimulate endogenous MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase] and ERK phosphorylation leading to an increase in cell proliferation, cell survival, transformation, tumorigenicity, invasion and vascular development. Many of these hallmarks of cancer can be reversed by treatment of cells with siRNA (small interfering RNA) to BRAF or by inhibiting MEK, indicating that BRAF and MEK are attractive therapeutic targets in cancer samples with BRAF mutations. In order to fully understand the role of oncogenic BRAF in cancer development in vivo as well as to test the in vivo efficacy of anti-BRAF or anti-MEK therapies, GEMMs (genetically engineered mouse models) have been generated in which expression of oncogenic BRaf is conditionally dependent on the Cre recombinase. The delivery/activation of the Cre recombinase can be regulated in both a temporal and spatial manner and therefore these mouse models can be used to recapitulate the somatic mutation of BRAF that occurs in different tissues in the development of human cancer. The data so far obtained following Cre-mediated activation in haemopoietic tissue and the lung indicate that V600E BRAF mutation can drive tumour initiation and that its primary effect is to induce high levels of cyclin D1-mediated cell proliferation. However, hallmarks of OIS (oncogene-induced senescence) are evident that restrain further development of the tumour.
Introduction
Cell growth is controlled by a number of key genes and, as a general rule of thumb, some of these genes need to be mutated before a cell becomes cancerous. Although more than 350 such 'cancer genes' have been identified to date, many others are thought to have been overlooked [1] . With the advent of whole genome sequencing, it is now possible to provide a molecular signature of individual cancers and this has opened up the possibility of identifying the full complement of cancer genes. One of the main efforts has centred on the sequencing of protein kinase genes [2] . In the first large-scale sequencing project of this type, the BRAF protein kinase gene was identified as a key growth Key words: BRAF, cancer, Cre-Lox, genetically engineered mouse model, proliferation, senescence. Abbreviations used: ERK, extracellular-signal-regulated kinase; GEMM, genetically engineered mouse model; LSL, Lox-Stop-Lox; MAPK, mitogen-activated protein kinase; MEF, mouse embryonic fibroblast; MEK, MAPK/ERK kinase; OIS, oncogene-induced senescence; PA, polyadenylation; siRNA, small interfering RNA; WT, wild-type. 1 To whom correspondence should be addressed (email cap8@le.ac.uk).
control gene that is frequently mutated in human cancers [3] . Although BRAF mutations are present in only ∼ 7% of human cancers as a whole, importantly, BRAF mutations are preponderant in malignant melanoma, being detected in up to 70% of all samples tested. They are also detected at a high frequency in papillary thyroid cancer (36-53%), serous ovarian cancer (∼ 30%) and colorectal cancer (5-22%). The vast majority of the BRAF mutations (>90%) represent a single nucleotide change of T to A at nucleotide 1799 resulting in a valine → glutamate mutation at residue 600 (V600E).
Over 40 different missense BRAF mutations have been detected in human cancer samples and these have been found to cluster in either the glycine-rich P loop or the activation segment of the BRAF kinase domain [4] . Wan et al. [5] analysed the kinase activity of a panel of 22 BRAF mutants and classified them as having either high, intermediate or impaired activity (Table 1) . A unifying feature of the high and intermediate activity mutants is that they disrupt the hydrophobic interaction between the P loop and the activation segment of the kinase domain. This results in destabilization of the inactive conformation of BRAF, thus stimulating its kinase activity leading to increased ERK (extracellular-signalregulated kinase) activation. However, the impaired activity mutants have less activity than the inactive WT (wild-type) kinase and thus do not fall into this neat model. Three of the four impaired activity mutants are still able to stimulate ERK and they appear to do this by activating CRAF through mechanisms that are not yet fully understood. The one remaining impaired activity mutant, D594V BRAF, behaves similarly to kinase-defective BRAF and does not stimulate ERK or CRAF activity (Table 1) . How this mutant is oncogenic is currently not clear, but it is certainly intriguing and further studies of it may well lead to the unravelling of novel functions for BRAF.
Data established from sequencing human tumour samples has led to some insight into the role of BRAF in the cancer phenotype. First, the data show that oncogenic BRAF and RAS mutations are mutually exclusive, rarely being present in the same cancer samples. This has been taken as evidence that BRAF and RAS contribute to cancer progression through similar mechanisms, most notably through their shared ability to activate the downstream MEK [MAPK (mitogenactivated protein kinase)/ERK]/ERK pathway, which is known to influence many cancer hallmarks [6] . Secondly, mutations in other raf genes are extremely rare and recent studies have indicated that CRAF requires mutation within the N-region of the kinase domain in addition to V492E CRAF mutation (the equivalent of a V600E BRAF mutation) in order to be converted into an oncogene [7] . Thirdly, BRAF mutations are present in benign naevi [8] that express senescent markers and V600E BRAF can induce senescence in melanocytes [9] . These observations are consistent with the view that OIS (oncogene-induced senescence) is a bona fide tumour-suppressive mechanism in the development of human cancers [10] and suggests that inactivation of key tumour suppressor genes such as CDKN2A may be necessary to unleash the full tumorigenic effects of V600E BRAF.
Mouse models for Raf-induced cancers
As elucidated above, studies of human cancer samples have not only led to the identification of BRAF as a human oncogene but also have provided mechanistic insight into how this oncogene operates. Further progress is hampered by the limited accessibility of human cancer material, particularly from early cancer lesions that may allow assessment of the progression of the disease. A major effort therefore has focused on the generation of GEMMs (genetically engineered mouse models) for cancer. Although there are many physiological differences between laboratory mice and humans, some of which have a big impact on cancer [11] , it is now possible to make the mouse more human-like and turn on/off oncogenic or tumour suppressor gene mutations at the right time in the right tissue. The availability of such accurate models is making a big impact on our understanding of the progression of cancer at the molecular level. GEMMs are also being applied to the development of anticancer therapies, including their use for target validation, toxicity studies and biomarker discovery [12] . The first mouse models for Raf -induced cancer were generated by expressing either the full-length craf gene or constitutively active craf-BxB under the control of the human surfactant protein-C promoter that directs expression to the type II epithelial cells lining the lung alveoli [13] . Both transgenics developed multifocal lung adenomas associated with high levels of phosphorylated ERK and high rates of cell proliferation that could be reduced by treatment with the MEK inhibitor CI-1040 [14] . Development of the tumours was also suppressed by bcl-2 deficiency [15] or by bag1 (Bcl-2-associated athanogene 1) haploinsufficiency [16] , suggesting that suppression of apoptosis co-operates in lung tumour induction. A similar approach was used to drive V600E BRaf expression from the bovine thyroglobulin promoter that directs expression to thyroid follicular cells [17] . This oncogene was observed to initiate multifocal tumours with evidence of progression to poorly differentiated carcinomas.
More recently, conditional knockin GEMMs using the Crelox system have been developed by modification of the endogenous BRaf locus using homologous recombination in ES cells [18, 19] . The model developed in our laboratory is illustrated in Figure 1 . In this model, the endogenous BRaf locus was modified such that an LSL (Lox-Stop-Lox) cassette was placed in intron 14 consisting of three loxP sites, a mini-cDNA encoding exons 15-18 of BRaf and a neo R cassette. Thus, in the absence of Cre recombinase, the WT BRaf protein is expressed with exons 15-18 being encoded by the mini-cDNA, whereas, in the presence of the Cre recombinase, deletion of the mini-cDNA and neo R cassette occurs such that V600E BRaf is expressed. The advantage of this system over those previously described is that the mutant BRaf is expressed at physiological levels and, by controlling the activity of the Cre recombinase, it is possible to mimic the situation that occurs in human cells where one copy of the normal BRAF gene is mutated somatically to V600E BRAF. So far this system has been used to induce somatic V600E BRaf expression in MEFs (mouse embryonic fibroblasts), the haemopoietic system using the inducible Mx1-Cre strain [18] and in the lung by intranasal instillation of adenoviral Cre [19] . Current efforts are being directed towards induction of V600E BRaf expression in other tissue types, particularly melanocytes and colonocytes as well as the development of mouse models for other BRAF oncogenic mutations.
What the data currently show
In the systems so far analysed, V600E BRaf is able to induce high levels of proliferation and this is associated with the induction of high levels of phosphorylated MEK/ERK and a large increase in cyclin D1 expression. Changes in other cell cycle proteins have not yet been reported although V600E BRaf has been shown to suppress p21 CIP1 expression in MEFs that may also contribute to increased S-phase progression [18] .
In the haemopoietic system, V600E BRaf induces a rapidly fatal acute myeloid leukaemia reminiscent of histiocytic sarcoma in which there is amplification of circulating cells of the macrophage lineage [18] . In the lung, V600E BRaf induces the formation of mixed papillary and solid adenomas that arise from amplification of alveolar type II pneumocytes within 6-8 weeks of Cre infection [19] . This phenotype can be reversed by treatment of mice with PD0325901, a MEK inhibitor structurally similar to CI-1040. However, at later times postinfection, fewer proliferating cells are observed in the lung adenomas, even though the MEK/ERK cascade remains active, and the expression of senescent markers including p19 ARF and Dec1 is induced. This result has been taken as evidence that, although V600E BRaf can promote a period of rapid cell proliferation, this is followed by OIS that restrains the further development of the tumours. Few of the adenomas spontaneously progress to adenocarcinomas although concomitant loss of TP53 or CDKN2A leads to more rapid cancer progression, presumably by overcoming OIS.
The phenotypes observed in V600E BRaf-expressing mice are similar in a number of ways to conditional knockin mice expressing oncogenic KRas but also demonstrate some differences. Expression of G12D KRas using the Mx1-Cre strain induces a different myeloproliferative disorder to V600E BRaf [20] , indicating that the two oncogenes have similar proliferative effects but target different populations of haemopoietic cells. Expression of oncogenic KRas in the lung leads to the similar development of adenomas that also express senescent markers [21] , but these progress more rapidly to adenocarcinomas than tumours induced by V600E BRaf [22] , suggesting that additional KRas effector pathways contribute to further tumour progression.
These initial studies have led to a model of how V600E BRaf may be involved in tumour development (Figure 2 ). In the first stage, the oncogene is able to initiate tumour development by promoting an initial dramatic wave of cell proliferation driven by activation of the MEK/ERK cascade and high levels of cyclin D1. In the case of certain haemopoietic neoplasias such as histiocytic sarcoma, this level of proliferation may be sufficient to give severe clinical symptoms. In the case of solid cancers, however, a second stage ensues involving the induction of at least some markers of OIS that constrain the further development of the tumours. In the third stage, inactivation of key tumour suppressors such as p16
INK4a or p19 ARF is required to overcome the senescent phenotype to further progress the disease. How V600E BRaf can promote striking cell proliferation on the one hand and cell cycle arrest on the other is a key quandary of this model and the role of the MEK/ERK pathway in both phenotypes will require the further analysis of GEMMs combined with cell culture model systems to resolve.
Conclusion
GEMMs are being used to recapitulate BRAF-induced cancers in humans. These mice are proving vital in dissecting how oncogenic BRAF contributes to cancer and so far have shown that mutation of BRAF can be an initiating event, that oncogenic BRAF acts similarly to oncogenic RAS and that OIS may be an important step in development of the disease, at least in the lung. Further studies of these and other mouse models for BRAF-induced cancers using a wider range of Cre delivery methods to activate the oncogene in different tissues will undoubtedly help provide a complete molecular picture of events leading to metastatic disease.
